(CEL) |
| 0 (0%) 01-14 13:29 |
| Open: | |
| High: | |
| Low: | |
| Volume: | 0 |
| Market Cap: | 0(M) |
| PE Ratio: | 0 |
| Exchange: | |
| Industry: | |
| Sector: |
| Technical analysis | ||||
 |
||||
| sell | buy | |||
| Resistance 2: | 3.90 |
| Resistance 1: | 3.75 |
| Pivot price: | 3.69 |
| Support 1: | 3.51 |
| Support 2: | 2.92 |
| 52w High: | |
| 52w Low: |
Financials
| EPS | -0.050 |
| Book Value | 4.010 |
| PEG Ratio | 0.00 |
| Gross Profit | 6.039 |
| Profit Margin (%) | -4.98 |
| Operating Margin (%) | 0.00 |
| Return on Assets (ttm) | -0.2 |
| Return on Equity (ttm) | -10.1 |
Company news
Tue, 13 Jan 2026
Beam Therapeutics: Pivoting From Platform To Execution Stage (NASDAQ:BEAM) - Seeking Alpha
Tue, 13 Jan 2026
For a Second Time, FDA Denies Approval of Tab-Cel in EBV+ PTLD - Targeted Oncology
Mon, 12 Jan 2026
Gilead Expects FDA Decision on Anito-Cel in First Quarter of 2026 - Precision Medicine Online
Mon, 12 Jan 2026
Katie Baker selected as the 2026-28 Center for Engaged Learning (CEL) Scholar - Elon University
Mon, 12 Jan 2026
FDA Hits Atara Biotherapeutics’ T-Cell Immunotherapy Tabelecleucel for EBV+ PTLD With Second CRL - CGTLive®
Mon, 12 Jan 2026
Cabaletta Bio Sets 2026 Strategy for Rese-cel Expansion - TipRanks
 StockChart iOS |
 StoxlineLite iOS |
StoxlineLite iOS |
 OptionCalc iOS |
|
StockChart Android |
StoxlineLite Android |
StoxlinePro Android |
OptionCalc Android |
